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Abstract 
 
Autoimmunity occurs in chronic obstructive pulmonary disease (COPD).  We 
describe an antigen microarray for detecting serum autoantibodies (AAbs) to 
determine how IgM, as well as IgG, AAbs distinguish patients with COPD from 
controls with a history of smoking without COPD. All COPD patients’ sera contained 
elevated levels of AAbs to some of 30 autoantigens.  There were significant 
differences in the autoantigenic specificities of IgM AAbs compared to IgG AAbs in 
the COPD sera: for example, AAbs to histone and scl-70 were mainly IgG, whereas 
AAbs to CENP-B and La/ssB were mainly IgM; by contrast, IgM and IgG AAbs to 
collagen-V were equally prevalent. Thus, a combination of IgM and IgG AAbs 
specific for multiple autoantigens are detected in all cases of COPD at a level at 
which all non-COPD controls are negative for AAbs.  This highlights the importance 
of different classes of AAbs to a range of autoantigens in COPD. 
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1. Introduction 
Smoking tobacco can have a variety of deleterious immunological 
consequences.  These include an increased risk of developing autoimmune diseases, 
e.g. rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Graves’ disease 
and multiple sclerosis [1].  Smokers also have up to a 50% risk of developing chronic 
obstructive pulmonary disease (COPD) [2], which involves a multitude of 
inflammatory processes that cause irreversible lung pathology, with contributions 
from both innate and adaptive immune mechanisms of tissue damage [3-7].  
Once COPD has become established in the body, progression of the disease is 
independent of exposure to tobacco fumes and continues irrespective of smoking 
cessation.  Having said that, the disease is treatable, and ceasing to smoke can slow its 
rate of progression, with earlier cessation having a greater benefit [2].  However, 
COPD is greatly under-diagnosed, with an average of 80% of cases worldwide being 
undetected [8].  Thus, better and earlier diagnosis of COPD could have a major 
impact on the morbidity and mortality associated with this disease. 
The intrinsic, self-perpetuating pathology of established COPD is consistent 
with the possible contribution of autoimmune mechanisms to the disease [9].  Indeed, 
there is now substantial evidence for the involvement of autoimmunity in COPD [10-
21], although it is not clear whether autoimmunity is driving the pathogenesis, or is a 
sequela of the inflammatory damage to the lungs and the associated increase in 
respiratory infections.  In addition, there are multiple systemic manifestations of 
COPD, including cardiovascular disease, metabolic disease, bone disease and 
cachexia [3, 22-25] – again, these could partly drive, or be driven by, autoimmune 
processes. 
 B lymphocytes make a significant contribution to the inflammatory infiltrate 
of the lungs in COPD [26] – particularly in cases dominated by emphysema [27]– and 
a number of reports have described the association of autoantibodies (AAbs) with the 
disease [10, 11, 13-20].  These studies have provided evidence for specific AAbs to 
multiple different autoantigens, with variations in the production of these AAbs 
between patients.  We previously reported evidence for the association of both 
disease-specific AAbs and natural AAbs with COPD [10]. These AAbs were detected 
in serum samples using ELISA.  There are, however, a number of advantages to be 
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gained over conventional ELISA by using protein microarray technology for the 
detection of AAbs (and other biomarkers) [28-30]: these include the small sample 
volumes required; the potential for detection of AAbs of multiple isotypes to many 
different autoantigens within a single assay; the possibility to include many more 
sample replicates; the ability to establish valid criteria for the exclusion of poor-
performing replicates (thereby reducing the coefficient of variation); and the much 
greater dynamic range of signal detection (5 orders of magnitude) compared to 
conventional ELISA (0 to 4 optical density units).  We describe here the development 
and application of an antigen microarray for the detection of different 
immunoglobulin classes of AAbs to a wide range of autoantigens in serum samples 
from COPD patients compared to controls with a history of smoking but without 
COPD.  Taking advantage of the multiplexing potential of the antigen microarray, this 
study highlights the heterogeneity of the autoantibody response between COPD 
patients in terms of both the range of autoantigens targeted and the contributions of 
autoantibodies of different classes to this response. 
 
2. Methods 
 
2.1 Patient Demographics 
A total of 54 patients with COPD and 10 control subjects without COPD but with >10 
pack year smoking history were recruited into the study.  The patients and controls 
were a mixture of current and ex-smokers.  COPD was diagnosed by clinical 
assessment, including history and examination, and by spirometry as FEV1:FVC 
<0.70.  The control subjects with a history of smoking had no clinical features of 
COPD and had normal spirometry.  Self-reported diabetes, rheumatoid arthritis and 
other metabolic and inflammatory diseases were exclusion criteria for the study.  The 
study was approved by the appropriate research ethics committees (REC ref. 
10/H0406/65; REC ref. 09/H0403/97; REC ref. 07/WSE04/05).  All the COPD 
patients were studied at clinical stability and were both on and off inhaled 
corticosteroids, as required clinically; no patients were taking oral corticosteroids. 
The COPD patients were categorized clinically on the basis of their Forced Expiratory 
Volume in one second % of predicted (FEV1%) as moderately severe (FEV1% 50-
80), severe (FEV1% 30-49) and very severe (FEV1% <30) [31]. Demographic 
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information is given in Table 1.  There were no statistically significant differences in 
the age ranges between any of the groups (by Kruskal-Wallis test with Dunn’s 
multiple comparisons test), nor in gender (by Fisher’s Exact test).                      
 
2.2 Microarray Assay 
The target antigens used to coat microarray slides are listed in Table  2.  The three 
microbial antigen preparations were chosen as being common recall antigens to 
natural infection or vaccination.  The potential autoantigens were selected on the basis 
of previous published evidence of their association with COPD and/or that they are 
well-characterised systemic autoantigens.  All antigens were buffer exchanged into 
PBS-Trehalose-Tween-20 buffer (PBS, 50 mM Trehalose and 0.01 % Tween-20) 
using Sephadex G10 in 1ml spin columns (MoBiTec GmbH, Gӧttingen, Germany) 
(Table 2).  The antigens were diluted to a concentration of 100 µg/ml, loaded into a 
384 well plate (Genetix), and arrayed onto the amino silane coated glass slides (Schott 
UK Ltd) using a Biorobotics Microgrid II arrayer (Digilab Genomic Solutions) and 
silicon contact pins (Parallel Synthesis Technologies, USA).  In addition, serial 
dilutions of human IgG and human IgM (Sigma-Aldrich, Poole, UK) were printed to 
enable relative concentrations of antibody responses to be determined.  
 
Printed slides were blocked for 1 hour in I-Block (Thermofisher, UK), and then were 
washed three times with PBST (containing 0.05 % Tween-20).  Avidin/biotin 
blocking buffers (Invitrogen Life Technologies Ltd, UK) were then added for 10 min 
each.  The slides were then incubated with serum (diluted 1:1000 in Dako antibody 
diluent) for 2h.  They were washed three times as before, and incubated with either 
1:20,000 dilution of biotinylated anti-IgG or 1:20,000 dilution of biotinylated anti-
IgM (Vectorlabs, Burlingame CA, USA).  The slides were washed three times as 
before, followed by addition of a 1:1000 dilution of streptavidin Cy5 (eBioScience 
Ltd, UK).  The slides were finally incubated in the dark for 15 min. Slides were then 
washed three times as before and rinsed with ultra-pure water. Slides were dried by 
centrifugation and scanned with a GenePix 4200 AL scanner (Molecular Devices 
LLC, Sunnyvale CA, USA) at 635 nm. 
 
 
 6 
2.3 Statistical Analysis 
Spot fluorescence was measured with Axon GenePix Pro 6 software (Molecular 
Devices LLC), and gpr files containing multi-parametric data were generated.  
Median fluorescence of each spot was measured (minus local background).  All spots 
with very low signal and poor spot morphology (i.e., spot circularity < 65) were 
excluded.  After filtration, data in gpr files were analysed in R (RPPAnalyzer, version 
3.0.2, 2013).  
Statistical analyses were performed using GraphPad Prism 7.0 software 
(GraphPad Software Inc., USA).  The correlation between ELISA and microarray 
techniques was performed with Pearson’s r (two-tailed) test; subsequent multiple 
comparisons between the two techniques were done by the Wilcoxon t test.  
Comparisons between antibodies levels in the different serum groups were performed 
using the non-parametric Kruskal-Wallis test (as many of the data sets were not 
normally distributed) with Dunn’s post-hoc test for multiple comparisons. A p-value 
≤ 0.05 was considered statistically significant. Individual autoantibody responses 
were presented semi-quantitatively by heat-maps and hierarchical clustering using 
Multiple Experiment Viewer Software (MEV, version 4.7.4). 
In order to maximise the specificity for COPD of the antibody detection 
compared to the controls without COPD, a very stringent cut-off for positivity was 
chosen – this was the 100th percentile plus 5% of the controls (i.e. [control maximum 
value] x 1.05). 
 
3. Results 
 
3.1 Autoantibody microarray assay development and validation 
A variety of surface chemistries, as well as printing buffers, blocking buffers 
and amplification systems were tested to generate a reproducible autoantibody array 
(Fig. 1).  A human IgG standard curve was validated and the lower limit of detection 
(LLoD) was calculated according to FDA guidelines (i.e. the standard deviation of the 
blank plus 2 SD).  IgG antibody responses of healthy control sera to control antigens 
(tetanus, Candida albicans and H. influenzae B) were initially determined and shown 
to interpolate within the IgG standard curve (Fig. 1Ai).  In addition, cross-reactivities 
of anti-IgG with IgM and of anti-IgM with IgG were tested (Fig. 1Aii).  When 
amplification (Genisphere) was used to increase the signal intensity, high levels of 
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non-specific binding were detected (Fig. 1Aii, left panels).  By contrast, without 
amplification, the anti-IgG and anti-IgM showed very little cross-reactivity with IgM 
or IgG, respectively (Fig. 1Aii, right panels); thus, the final assay did not include an 
amplification step.   
In order to validate the optimised microarray assay, it was compared with a 
conventional ELISA for the detection of antibodies to candida and tetanus antigens in 
sera from healthy individuals (Fig. 1Bi).  There was a high degree of correlation for 
antibody detection by the two methods (p=0.0002 for antibodies to Candida, and 
p=0.0007 for antibodies to tetanus).  However, it is apparent that the microarray 
showed a greater degree of sensitivity compared to the ELISA in terms of the 
interpolated levels of IgG detected (Fig. 1Bi). 
 
3.2 IgG and IgM responses to microbial control antigens 
 The sensitivity of the antigen microarray was verified by detecting antibodies 
to tetanus, Candida and H. influenzae B (Hib) in the sera of controls without COPD 
and patients with moderate, severe or very severe COPD (Fig. 2).  As expected, 
subjects showed a broad range of antibody levels and there were no overall significant 
differences between the groups of smokers and COPD patients, except for 
significantly raised IgM antibodies to Candida in patients with very severe COPD 
(p=0.0129).  Very few patients had levels of antibodies to tetanus and Hib above the 
cut-off of those in the controls (see Methods section for the definition of the cut-off).  
By contrast, 39% of patients (21/54) had levels of antibodies to candida above the cut-
off of the controls (9/21 moderate, 10/27 severe, 2/6 very severe): of these, 7 had 
raised levels of IgG anti-Candida alone, 8 had raised IgM anti-Candida alone, and 6 
had raised levels of both IgG and IgM anti-candida (Figs. 3a and 4a – heat maps).         
 
3.3 IgG responses to a panel of autoantigens 
 The controls’ and COPD patients’ sera were screened for IgG autoantibodies 
(AAbs) to the 30 autoantigens listed in table 2 (see also Fig. 1Bii).  Examples of the 
IgG AAbs detected are shown in fig. 3b.  A broad spectrum of concentrations of most 
AAbs were observed, with significant overall increases in the COPD groups relative 
to the controls for a minority of autoantigens (examples shown in fig. 3b are AAbs to 
collagen V and histone in the moderately severe COPD group, and also AAbs to 
histone in the very severe COPD group).  However, relative to the cut-off of IgG AAb 
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levels in the controls’ sera, most COPD patients in all three severity groups showed 
elevated AAbs specific to particular autoantigens.  This is summarized in the heat 
map in fig. 3a, in which shaded squares indicate AAb levels above the cut-off of the 
non-COPD controls with a smoking history (referred to as ‘smokers’ in the figure).  
On this basis, the mean number of IgG AAb reactivities detected in each group was: 
controls, 0 (as expected with a cut-off 5% above the maximum value of this group); 
moderate COPD, 3.5; severe COPD, 2.6; very severe COPD, 4.5.  Overall, 89% of the 
COPD patients had significant IgG AAb reactivities to between 1 and 8 autoantigens.  
On the other hand, the prevalence of IgG AAbs specific for different autoantigens 
varied greatly: for example, none of the patients’ sera had significantly elevated levels 
of IgG specific for azurocidin, collagen II, keratin-18, keratin-8 or pANCA, whereas 
at least 19/54 patients had elevated IgG specific for collagen V, histone and scl-70. 
 
3.4 IgM responses to a panel of autoantigens 
 The controls’ and COPD patients’ sera were also screened for IgM AAbs to 
the panel of autoantigens (Fig. 4).  The examples in fig. 4b show that, as for the IgG 
AAbs (Fig. 3b), a broad range of concentrations of IgM AAbs were observed for most 
autoantigens, with significant elevation of median levels in the COPD patients 
compared to the controls (referred to as ‘smokers’ in the figure) for only a few 
autoantigens (e.g. for AAbs to CENP-B, collagen V, RNP/SM and La/ssB).  
Interestingly, IgM AAbs to collagen-I were significantly lower in all the COPD 
groups compared to the control group.  However, similar to the IgG AAbs, most 
COPD patients showed elevated levels of IgM AAbs specific for particular 
autoantigens relative to the cut-off of the controls’ IgM AAbs (Fig. 4a).  The mean 
number of IgM AAb reactivities detected in each group was: controls, 0; moderate 
COPD, 3.2; severe COPD, 3.1; very severe COPD, 4.8.  Overall, 93% of the COPD 
patients had significant IgM AAb reactivities to between 1 and 11 autoantigens.  
There were, however, some striking differences in the autoantigenic specificities of 
the IgM AAbs in the COPD sera compared to the IgG AAbs: for example, no COPD 
sera showed elevated IgM reactivity with collagen I, histone, nucleosome or 
RNP/SM(free), but 31 had elevated IgM specific for CENP-B, and 23 to La/ssB (Fig. 
4a). 
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3.5 Combined IgM and IgG responses to a sub-panel of autoantigens 
 The marked differences in the specificities for different autoantigens of the 
IgM and IgG AAbs in the COPD patients’ sera indicates that, considering the IgM 
and IgG AAbs in combination, rather than separately, may be more informative about 
their association with COPD.  Figure 5a shows a heat map of the occurrence of 
elevated levels of IgM (dark grey), IgG (light grey), or both IgM and IgG (black) 
antibodies relative to the cut-off of the control group with a smoking history but 
without COPD (referred to as ‘smokers’ in the figure).  This figure shows responses 
to both the autoantigens and the microbial control antigens. The figure was generated 
by allowing unsupervised clustering, both by antigens and by subjects.  By definition, 
none of the controls with a smoking history show positivity to any antigens because 
of setting the cut off for positivity at 105% of the maximum control responses; thus, 
all the controls cluster at the left of the heat map.  Increasing numbers of antigens 
recognized by antibodies in the COPD patients’ sera are shown from left to right of 
the heat map.  This does not clearly differentiate the COPD patients by disease 
severity, indicating that the occurrence of these antibodies is related to COPD per se, 
rather than severity of COPD.  It is, however, apparent that the six patients with very 
severe COPD cluster towards the centre and right of the heat map, indicating slightly 
higher numbers of antigenic specificities than in the moderate and severe COPD 
patients.  Indeed, the mean number of antigens recognized per sample were: controls, 
0; moderate COPD, 7.0; severe COPD 5.8, very severe COPD, 9.7.  Considering both 
IgG and IgM antibodies above the cut-off applied, none of the controls had raised 
levels of antibodies and all the COPD patients were positive for AAbs to between 1 
and 13 of the autoantigens (plus antibodies to candida).  Thus, on this basis, the assay 
gave 100% specificity and 100% sensitivity for the detection of AAbs in COPD 
patients compared to the controls with a smoking history but without COPD. 
 The clustering of antigens shows two groups that are predominantly 
recognized by antibodies in the sera of at least 5 COPD patients (indicated by the 
thick grey lines to the right of the heat map in figure 5a) – one at the top of the heat 
map (6 antigens) and the other in the lower half of the heat map (16 antigens, 
excluding pANCA).  The 6 antigens in the top group are recognised predominantly by 
IgM class antibodies (69% of responses), and the 16 antigens in the lower group are 
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recognised predominantly by IgG antibodies (66% of responses). Figure 5b 
summarises the responses to this sub-panel of 22 antigens and shows that they can be 
divided into three groups based on whether the response in COPD patients is 
dominated by IgG AAbs (left panel), IgM AAbs (centre panel), or that IgM and IgG 
AAbs are equally prevalent (right panel; including also antibodies to Candida).  
Overall, this emphasizes the value and importance of assessing different classes of 
AAbs to fully characterize the autoimmune response in COPD patients.  
 
4. Discussion 
 There is substantial evidence for the association of AAbs of various 
specificities with COPD, but most previous studies have examined AAbs only of IgG 
class, or have not specified the antibody isotypes detected [11, 13, 15-19, 32].  Here 
we demonstrate that AAbs recognize different, but overlapping, sets of multiple 
autoantigens in COPD.  Thus, the combination of these different classes of AAbs 
should be evaluated to give a complete picture of the role of autoimmunity in COPD.  
This conclusion was reached by examining IgG and IgM classes of AAbs.  It might be 
argued that IgG AAbs are more relevant to disease than IgM on the basis that class 
switching suggests antigen-driven progression of the autoimmune response [19].  
However, there are also numerous examples in which IgM AAbs play important roles 
in disease pathogenesis [33-40].  Further insights might also be gained by detecting 
IgA AAbs (given the important role of IgA at mucosal surfaces), and by measuring 
IgG subclasses [14].  There may also be value in assessing the IgD class for AAb 
activity in COPD in view of its role in humans in the upper respiratory tract [41, 42]. 
 Although we found that most COPD patients express IgG and IgM AAbs, only 
a minority had detectable IgM and IgG AAbs specific for the same antigen.  There 
was also a clear distinction between the autoantigens that were principally recognized 
by IgM or IgG AAbs.  It is unclear why the B cell response to some autoantigens 
usually undergoes class switching whereas class switching occurs less frequently in 
the response to other autoantigens.  This does not appear to relate to the nature of the 
autoantigens, since a diverse range of types of nuclear, cytoplasmic and extra-cellular 
proteins serve as autoantigens in the responses dominated by IgG AAbs, IgM AAbs, 
or showing an equal representation of IgG and IgM AAbs (Fig. 5b).  A precedent for 
IgG and IgM AAbs having different antigenic specificities is seen in autoimmune 
hemolytic anemia, in which IgG AAbs mainly target antigens of the Rh system and 
 11 
IgM AAbs target the I/i system [43]. Some of the AAb specificities documented in 
our study have been reported previously in COPD patients, e.g. antibodies to 
(cyto)keratin-18 [15] and to CENP-B [17].  It is particularly interesting that Packard 
et al. employed an antigen microarray platform similar to the one we used, and 
reported a similar range of AAb specificities in COPD, although they presented data 
for IgG AAbs only [19].   
The nature of the autoantigens targeted and, therefore, the specificities of the 
AAbs produced in COPD, could relate both to the immune/inflammatory processes in 
the lungs and to the systemic manifestations of COPD.  Indeed, the broad range of 
autoantigens targeted, with different combinations targeted in different patients, is 
reminiscent of classical systemic autoimmune diseases like systemic lupus 
erythematosus [44].  This supports the need to assess AAbs to a broad range of 
autoantigens to gain a full picture of the autoimmune response in COPD.   
Collagen-I is a major component of lung tissue and both decorin and collagen-
V are found in association with collagen-I; thus, the targeting of these autoantigens 
could be associated with the lung pathology in COPD.  Indeed, we have previously 
reported that AAbs to collagen-V can be eluted from the lung tissue of COPD patients 
[10]. In that study, in which AAbs were also detected in sera from a small number of 
subjects by ELISA, we observed decreased IgG AAb reactivity with collagen-I in the 
sera of 6 COPD patients compared with 6 never-smoker controls, and proposed that 
what was detected were natural autoantibodies that may have been sequestered from 
the circulation into the inflamed lung in COPD [10].  In the current study, we 
observed elevated levels of IgG anti-collagen-I in 9/54 (i.e. 1/6th) of the COPD 
patients.  Thus, the relative infrequency of IgG AAbs specific for collagen-I in the 
sera of COPD patients may explain why they were not detected in the small sample of 
6 patients studied previously [10].  On the other hand, the median levels of IgG anti-
collagen-I in the sera of severe and very severe COPD patients in the present study 
were lower than that of the controls (Fig. 3b), consistent with our previous report [10].  
The levels of collagen-I-binding IgM AAbs detected by microarray in the present 
study were also lower in COPD patients than in the controls (Fig. 4b).  In this assay, 
therefore, we may be observing the consequences of sequestration of natural 
antibodies of both IgG and IgM classes from the circulation to the lung, as well as 
detecting specific IgG anti-collagen-I AAbs in a minority of patients.   
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Many of the AAbs detected in the present study were specific for autoantigens 
that are ubiquitously expressed nuclear and cytoplasmic proteins usually associated 
with systemic autoimmune disease like systemic lupus erythematosus, scleroderma, 
systemic sclerosis, mixed connective tissue disease and myositis.  A significant 
proportion of COPD patients also suffer from systemic co-morbidities, including 
cardiovascular, metabolic and bone disease, and cachexia [22-25].  Indeed, we have 
documented the occurrence of elevated levels of multiple circulating cytokines in 
COPD, consistent with the development of systemic pathologies [29].  In this context, 
the occurrence of AAbs specific for systemic autoantigens in COPD may relate both 
to the lung-associated and systemic manifestations of the disease.  For example, AAbs 
to PL-7, which were detected in 50% of the COPD patients, are known to occur in 
myositis with associated interstitial lung disease [45]. 
The aim of the present study was to determine how IgM and IgG class AAbs 
differ between patients with COPD and controls with a smoking history but without 
COPD; we therefore chose a particularly stringent cut-off for positivity that was 
above the range of the AAb levels in the non-COPD controls with a smoking history.  
Even then, all of the COPD patients were classified as positive for IgG and/or IgM 
AAbs to one or more of the autoantigens (i.e. the assay was 100% sensitive and 100% 
specific for COPD.)  Considering either IgG or IgM AAbs alone, even with the full 
set of 30 antigens, gave lower sensitivity than considering IgG and IgM AAb in 
combination (sensitivities of 89% and 93% for IgG and IgM AAb, respectively). 
A further point of interest for future study is the possible prognostic value of 
measuring AAbs as biomarkers of the development of COPD: clearly, this would 
need to be addressed by prospective studies of COPD development involving 
measurements of AAbs (of multiple autoantigenic specificities and Ig classes) in 
smokers who go on to develop COPD compared to those who do not. 
A related issue is whether the development of autoimmunity and the 
production of AAbs in COPD is a primary or secondary event; i.e. does autoimmunity 
contribute to the development of COPD, or is a consequence of COPD (or other co-
existent disease) becoming established?  Our study does not directly address this 
question and, again, prospective studies are needed to provide insights into this.  
Others have reported correlations between levels of AAbs and COPD severity [14, 
15].  We did not observe a statistical association of this type in the present study, 
although the small group of patients with very severe COPD (based on very low 
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FEV1%) did have the highest number of IgM and/or IgG antibody specificities.  In 
particular, all 6 patients with very severe COPD were positive for IgM anti-CENP-B, 
and 5/6 were positive for IgG anti-histone. 
In addition to the measurement of AAbs, the observation that over a third of 
COPD patients had elevated levels of antibodies to Candida is consistent with the 
recognized increase in oral candidiasis in COPD, particularly associated with use of 
inhaled corticosteroids [46]. 
Limitations of this study include the relatively small group sizes (which 
precluded further sub-classification of clinical phenotypes), the lack of full definition 
of co-morbidities and the variable use of inhaled corticosteroids by the COPD 
patients.  The range of autoantigens could also be extended – for example, 
autoantibodies to elastin have been reported to be associated with emphysema [16], 
although some other studies were unable to confirm an association between anti-
elastin and COPD [47-49].   
 
5. Conclusions 
This study demonstrates, using antigen microarray technology, that COPD 
patients not only show a significant increase in circulating AAbs to a broad range of 
autoantigens, but also that IgM and IgG AAbs show different autoantigenic 
specificities.  This combination of IgM and IgG AAbs specific for multiple 
autoantigens clearly distinguishes the adaptive immune profile of COPD patients 
from that of controls with a history of smoking but without COPD. 
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Table 1.  Demographic information for the study groups. 
 
 
 
Group 
Moderate 
COPD 
 n=21 
Severe  
COPD 
n=27 
Very severe  
COPD 
 n=6 
Control 
Smoker  
n=10 
 
Age 
Median (range) 
 
67 (49-79) 65 (59-77) 63 (57-75) 66 (62-81) 
 
Gender 
Male/Female 
		
8/13 14/13 3/3 6/4 
 
FEV1% 
Median (range) 
 
57 (50-80) 42 (30-49) 22 (13-29) 109 (83-134) 
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Table 2.  Antigens used in the microarray assay. 
 
Antigens Manufacturer 
Haemophilus influenzae B, Tetanus toxoid and Candida 
albicans  
National institute 
for Biological 
standards and 
control (NIBSC) 
Azurocidin, GBM, histone, HNRPD, La/ssB, Nucleosome, 
cANCA, pANCA, PL-7, PL-12, Ribosomal p, RNP/sm, RNP 
68k (sm free), RNP/sm free, Ro/ssA, Ro-52, SCL-70, sm 
antigen and CENP-B 
Arotec Diagnostics, 
Wellington, NZ 
Collagen II 
Merck Millipore, 
Billerica, MA, 
USA 
Collagen I, collagen III, collagen IV, collagen V, Keratin 18 
and Keratin 8 Sigma-Aldrich 
Decorin, Aggrecan (AGC1), Serum amyloid 2(SAA2) and 
Cytochrome c Abnova, UK 
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Figure legends 
 
Figure 1.  Development and validation of the autoantibody microarray assay.  
The top panel gives a schematic of the central aspects of the autoantibody microarray 
technology.  Ai, interpolation of the levels of antibodies detected in normal human 
sera specific for tetanus , candida and H. influenzae antigens into the IgG standard 
curve.  Aii, demonstration of the specificity of anti-IgG and anti-IgM secondary 
antibodies without the application of signal amplification reagent (right panels) 
compared to the lack of specificity when signal amplification reagent (Genishpere) is 
used (left panels).  Bi, comparison of the optimised microarray assay and 
conventional ELISA for detection of antibodies to candida and tetanus in normal 
human sera.  Bii, example of the layout of autoantigens in the optimised microarray 
for the detection of serum autoantibodies.  
 
Figure 2.  Detection by microarray of antibodies specific to microbial antigens in 
sera from control smokers (S) and COPD patients.  a) IgG antibodies to tetanus, 
candida and H. influenza.  b) IgM antibodies to tetanus, candida and H. influenza.  
Solid bars represent median values and dashed lines represent the cut-off of the 
control smoker group ([maximum value] x 1.05).  * indicates where the distribution of 
the antibody levels in a group of COPD patients as a whole is significantly greater 
than that of the non-COPD controls with a history of smoking (referred to as 
‘smokers’ in the figure) (0.05>p>0.01). 
 
Figure 3.  Detection by microarray of IgG AAb specific to autoantigens in sera 
from COPD patients.  a) Heat map showing, in the shaded squares, antibody 
responses above the cut-off of the non-COPD controls with a history of smoking 
(referred to as ‘smokers’ in the figure) ([maximum value] x 1.05).  B) Scatter plots 
showing examples of the distribution of the IgG AAb levels summarised in the heat 
map in (a).  Solid bars represent median values and dashed lines represent the cut-off 
of the non-COPD controls with a history of smoking (referred to as ‘smokers’ in the 
figure) ([maximum value] x 1.05).  Asterisks indicate where the distribution of AAb 
levels in a group of COPD patients as a whole is significantly greater than that of the 
control ‘smoker’ group (*0.05>p>0.01; **0.01>p>0.001). 
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Figure 4.  Detection by microarray of IgM AAb specific to autoantigens in sera 
from COPD patients.  a) Heat map showing, in the shaded squares, antibody 
responses above the cut-off of the non-COPD controls with a history of smoking 
(referred to as ‘smokers’ in the figure) ([maximum value] x 1.05).  b) Scatter plots 
showing examples of the distribution of the IgM AAb levels summarised in the heat 
map in (a).  Solid bars represent median values and dashed lines represent the cut-off 
of the non-COPD controls with a history of smoking (referred to as ‘smokers’ in the 
figure) ([maximum value] x 1.05).  Asterisks indicate where the distribution of AAb 
levels in a group of COPD patients as a whole is significantly greater than that of the 
control ‘smoker’ group (*0.05>p>0.01; **0.01>p>0.001). 
 
Figure 5.  Compilation of the IgG and IgM antibodies specific to autoantigens 
and microbial antigens in sera from COPD patients.  a) Heat map showing IgG 
alone (light grey), IgM alone (dark grey) and IgG+IgM (black) antibody levels above 
the cut-off of the non-COPD controls with a history of smoking ([maximum value] x 
1.05).  The order of subjects (horizontal axis) and antigens (vertical axis) was 
determined by unsupervised clustering of the data.  b) Number of COPD patients in 
whose sera antibodies specific for the indicated autoantigens (plus Candida) were 
detected that were IgG class only (light grey) IgM class only (dark grey), or a 
combination of IgG and IgM classes (black). 
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